Target intelligence / Profile preview

Dicer ribonuclease III (DICER)

Target
DICER
Molecular classification
Enzyme (specifically Endoribonuclease), Ribonuclease III family (type III RNase), RNA interference protein, MicroRNA processing protein
01

Overview

Dicer ribonuclease III (commonly called Dicer or DICER1) is a multidomain, magnesium-dependent endoribonuclease belonging to the RNase III family. Structurally, it contains a helicase domain, DUF283, a PAZ domain, a connector helix, two RNase III domains (IIIa and IIIb), and a C-terminal dsRNA-binding domain. Dicer functions as a molecular ruler, binding double-stranded RNA and cleaving these precursors into short fragments (typically 21–25 nucleotides) with a 2-nucleotide 3' overhang. This activity is central to the generation and maturation of microRNAs (miRNAs) and small interfering RNAs (siRNAs), enabling sequence-specific regulation of gene expression (RNA silencing). In humans, Dicer is encoded by the DICER1 gene, which is crucial for development, differentiation, antiviral defense, and prevents oncogenic transformation—loss or mutation can result in disease or promote cancer. Dicer is not a receptor, transporter, or channel; it is a catalytic enzyme essential for RNA processing.

Other names
DicerDICER1 (human gene name)Ribonuclease III DicerDicer enzymeRNase III Dicer
02

Mechanism of action

For drugs or therapeutics that modulate Dicer: inhibition or enhancement of dsRNA cleavage function, affecting production of miRNA/siRNA and downstream gene silencing. RNAi therapeutics: require Dicer activity to generate active siRNA/miRNA fragments for target mRNA silencing.

03

Biological functions

RNA interference (RNAi) pathwayMicroRNA (miRNA) maturationSmall interfering RNA (siRNA) processingRegulation of gene expression at the post-transcriptional levelDefending against viral RNA in some contextsNoncanonical functions in the nucleus (chromatin regulation, DNA damage response)
04

Disease associations

Cancer (altered Dicer activity is linked to tumorigenesis, some cancers have mutations in DICER1)Neurodegenerative disease (miRNA dysregulation is implicated)Infection (viral manipulation of host RNAi pathways, antiviral defense)Other genetic disorders (DICER1 syndrome, which predisposes to various tumors)
05

Safety considerations

Therapeutic manipulation may cause off-target gene silencing or unintended immune activationLoss-of-function mutations can promote tumorigenesis and developmental defectsOver-inhibition could lead to vital miRNA deficiency affecting cell survival or differentiation
06

Interacting drugs

No direct approved drugs target Dicer itself; however, small molecules, RNA-based inhibitors, and modulators of RNAi that functionally interact with Dicer or its pathway are under investigation

2 more in the full profile.

07

Biomarkers

DICER1 mutation status is used as a biomarker for certain familial tumor syndromes and cancersmiRNA/siRNA profiles in patient tissue; these depend on Dicer activity and are used in research/settings for prognosis or diagnosis

Beyond the preview

Go deeper on Dicer ribonuclease III (DICER).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dicer ribonuclease III (DICER).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call